Clinical Trials Sponsored by Orion Corporation, Orion Pharma

Total 141 results

Orion Corporation, Orion Pharma

Completed

Safety and Pharmacokinetics of ODM-209 (STESIDES)

Advanced Breast Cancer | Metastatic Breast Cancer | Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

Finland, France, Denmark
Orion Corporation, Orion Pharma

Completed

Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing (EASYRELIEF)

Asthma

Finland
Orion Corporation, Orion Pharma

Completed

Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler (TEMPO)

Healthy Volunteers

Finland
Orion Corporation, Orion Pharma

Completed

Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS (REFALS)

Amyotrophic Lateral Sclerosis

Canada, United States, Australia, Austria, United Kingdom, Germany, Finland, Spain, France, Italy, Sweden, Netherlands, Belgium, Ireland
Orion Corporation, Orion Pharma

Completed

Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler (FINDA)

Healthy Volunteers

Finland
Orion Corporation, Orion Pharma

Terminated

Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway (BufoSwitch)

Asthma | COPD

Norway
Orion Corporation, Orion Pharma

Completed

Blood-Brain Barrier Penetration of Therapeutic Agents in Human (BRIAN)

CNS Disease

Finland
Orion Corporation, Orion Pharma

Completed

Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler (TIOPIF)

Healthy Volunteer | COPD

Estonia
Orion Corporation, Orion Pharma

Completed

Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI)

Asthma

Finland
Orion Corporation, Orion Pharma

Completed

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Prostate Cancer

United States, United Kingdom, Finland, France, Estonia, Czech Republic
Orion Corporation, Orion Pharma

Completed

To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product (BUFODIL)

Asthma

Bulgaria
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study of Single Doses of ORM-12741 (Nebula PK 1)

Healthy

Finland
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study in Healthy Males (NOCOF)

Parkinson's Disease

Finland
Orion Corporation, Orion Pharma

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers (NOCOS)

Healthy

Germany
Orion Corporation, Orion Pharma

Completed

Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide Diskus

Asthma

Finland
Orion Corporation, Orion Pharma

Completed

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations (PARPOC)

Parkinson's Disease
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Pilot Study on Budesonide/Formoterol

Healthy

Germany
Orion Corporation, Orion Pharma

Completed

Safety and Pharmacokinetic Study With Multiple Ascending Doses of ORM-12741

Healthy

France
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study of Spironolactone 25 mg, 50 mg and 100 mg Tablets

Healthy

India
Orion Corporation, Orion Pharma

Completed

Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets Under Fed Conditions

Healthy

Finland
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler

Healthy

Finland
Orion Corporation, Orion Pharma

Completed

Comparison of PEG Solutions With and Without Electrolytes in the Treatment of Constipation (PEGorion)

Constipation

Finland
Orion Corporation, Orion Pharma

Terminated

PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding

Parkinson´s Disease

Finland
Orion Corporation, Orion Pharma

Active, not recruiting

Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer (CYPIDES)

Prostate Cancer Metastatic

France, United Kingdom, Finland, United States
Orion Corporation, Orion Pharma

Terminated

Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension (REFALS-ES)

Amyotrophic Lateral Sclerosis

Canada, United States, Australia, Germany, Belgium, Finland, Spain, Austria, Italy, France, Ireland, Netherlands, Sweden, United Kingdom
Orion Corporation, Orion Pharma

Completed

Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product (FORELLI)

Healthy Volunteers

Finland
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Tiotropium Easyhaler® and Spiriva® HandiHaler® (TESSA)

Healthy Volunteers

Finland
Orion Corporation, Orion Pharma

Completed

Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours (KIDES-203)

Solid Tumours

France, Finland, Spain, Italy, Denmark, United Kingdom
Orion Corporation, Orion Pharma

Completed

Efficacy and Safety of Remo-Wax for Removal of Impacted Earwax (Remo-Wax)

Cerumen Impaction of Both Ears

Lithuania
Orion Corporation, Orion Pharma

Completed

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC) (COMPOC)

Parkinson's Disease

Finland, Germany, Hungary, Latvia
Orion Corporation, Orion Pharma

Completed

Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Ireland, Netherlands, United Kingdom, Germany
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic of Levodopa Study in Healthy Males

Parkinson Disease

Finland
Orion Corporation, Orion Pharma

Completed

Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients.

Heart Failure

Sweden
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study to Compare Absorption of Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Asthma

Finland
Orion Corporation, Orion Pharma

Completed

Study to Evaluate Initiation of Stalevo in Early Wearing-off (SENSE)

Parkinson's Disease

Germany, Sweden, United Kingdom
Orion Corporation, Orion Pharma

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy Volunteers (NOCIFIM)

Healthy

Germany
Orion Corporation, Orion Pharma

Completed

Safety and Tolerability Study With Single Ascending Doses of ODM-102

Healthy Volunteers

Finland
Orion Corporation, Orion Pharma

Completed

Efficacy and Safety of Ibuprofen in Patients With Ankle Injuries

Pain

Finland
Orion Corporation, Orion Pharma

Completed

Efficacy and Safety of Ibuprofen in Patients With Ankle Injuries

Pain

Finland
Orion Corporation, Orion Pharma

Completed

Phase I Pharmacokinetic Study (SALBLOCK) (SALBLOCK)

Healthy Volunteer Study

Finland
Orion Corporation, Orion Pharma

Completed

Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens (PARTEST)

Parkinson's Disease

Finland, Sweden
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers (Reco-Pilot)

Asthma

Finland
Orion Corporation, Orion Pharma

Completed

Levodopa Concentration Profile With Stalevo 75/125 mg (NEWSTA)

Parkinson's Disease

Finland
Orion Corporation, Orion Pharma

Completed

Dexmedetomidine Versus Propofol for Continuous Sedation in the Intensive Care Unit (ICU) (Prodex)

Continuous Sedation in Initially Sedated Adults in ICU

Finland, United Kingdom, Belgium, Germany, Netherlands, Russian Federation, Switzerland
Orion Corporation, Orion Pharma

Completed

A PET Study With ORM-12741

Healthy

Finland
Orion Corporation, Orion Pharma

Completed

Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets

Healthy

Finland
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study of ORM-12741 in Healthy Volunteers

Healthy Volunteers

Finland
Orion Corporation, Orion Pharma

Completed

Safety and Tolerability Study With Multiple Ascending Doses of ORM-12741

Healthy

France
Orion Corporation, Orion Pharma

Completed

Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU (DEX PK)

Pharmacokinetics | Sedation

Finland
Orion Corporation, Orion Pharma

Completed

Peroral Levosimendan in Chronic Heart Failure

Heart Diseases | Chronic Heart Failure

Finland

Clinical Trials Sponsored by Orion Corporation, Orion Pharma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations